ArticleClinical, cosmetic and investigational dermatology2026
Real-World Use of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Single-Centre Retrospective Descriptive Analysis.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Upadacitinib is an oral Janus kinase 1 inhibitor for moderate-to-severe atopic dermatitis, although real-world evidence from Middle Eastern clinical practice remains limited. The objective of the present study was to describe treatment patterns, physician-documented response, symptom improvement, adverse events, discontinuation, and laboratory monitoring in patients treated with upadacitinib for moderate-to-severe atopic dermatitis. Methods: This retrospective descriptive analysis included 30 patients treated with upadacitinib at King Fahd University Hospital between 2023 and 2025. Data were extracted from clinical records and summarized descriptively. Outcomes included dose, treatment duration, response timing, itch and sleep improvement, flare reduction, adverse events, laboratory abnormalities, and discontinuation. Results: Clinical response was evaluable in 28 patients; two were not evaluable because follow-up documentation was insufficient or unclear. Qualitative physician-documented improvement was recorded in 27 of the 28 evaluable patients, and response was documented within four weeks in 23 of 28. Among patients with paired symptom data, the median pruritus NRS decreased from 8.0 to 2.0, the median sleep-disturbance rating decreased from 8.0 to 2.0, and monthly flare frequency decreased from 5.0 to 1.0. A reduction of at least four points in pruritus NRS occurred in 25 of 28 patients. Retained adverse events occurred in 13 patients. Five patients discontinued treatment, including two because of safety, infection, or laboratory concerns. Conclusion: Frequent physician-documented improvement was observed in patients with evaluable follow-up; however, five patients discontinued upadacitinib, including two due to safety, infection, or laboratory concerns. These descriptive findings suggest careful interpretation, patient selection, baseline assessment and frequent clinical and laboratory follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.